key: cord-0758137-383c9qai
authors: Zhong, Zhimei; Li, Hongyuan; Zhu, Jieyun; Ji, Pan; Li, Bocheng; Pang, Jielong; Zhang, Jianfeng; Liang, Xiangdong
title: Clinical characteristics of 2,459 severe or critically ill COVID-19 patients: A meta-analysis
date: 2021-02-05
journal: Medicine (Baltimore)
DOI: 10.1097/md.0000000000023781
sha: e495843b86de7ecf010009b7a5e197950563f90c
doc_id: 758137
cord_uid: 383c9qai

Our study aims to summarize the clinical characteristics of patients with severe or critically ill coronavirus disease 2019 (COVID-19). Five databases were electronically searched to collect studies describing clinical characteristics of severe or critically ill COVID-19 patients and published between January 1, 2020 and April 12, 2020. Three reviewers independently collected the literature, extracted the required data, and assessed the risk of publication bias of the included studies before including the studies in the meta-analysis. A total of 40 studies involving 2459 patients with severe or critically ill COVID-19 patients were included. Meta-analysis showed that a greater proportion of severe or critically COVID-19 patients were male (62.3%), and the 2 main clinical symptoms were fever (87.4%) and cough (66.3%). Other common clinical symptoms included dyspnea (45.3%), chest tightness (37.4%), fatigue (36.6%), and expectoration (31.9%). Minor symptoms included myalgia (19.5%), dizziness (11.5%), headache (11.4%), diarrhea (11.2%), pharyngalgia (11.0%), nausea, and vomiting (5.9%). Most patients showed elevated levels of C-reactive protein (83.5%) and D-dimer (73.3%), lymphopenia (70.3%), and normal leukocyte counts (56.9%). Other findings included abnormal levels of liver function (39.8%), elevated procalcitonin (36.6%), leukocytosis (21.7%), thrombocytopenia (19.0%), and leucopenia (18.2%). Most patients showed acute respiratory distress syndrome (60.8%). Other complications included acute cardiac injury (37.1%), shock (32.0%), and acute kidney injury (22.0%). The most common symptoms of severe or critically ill COVID-19 patients were fever and cough. Most patients showed lymphopenia, elevated levels of C-reactive protein and D-dimer. A large percentage of patients progress to ARDS, acute cardiac injury, acute kidney injury and shock were also common.

Since December 2019, many cases of novel coronavirus-infected pneumonia (NCIP) have been detected in Wuhan, China. In a short period, NCIP quickly spread to the whole world. On January 30, World Health Organization (WHO) declared NCIP to be an international public health emergency. [1] And on February 11, the disease was named coronavirus disease 2019 . [2] At present, the epidemic of COVID-19 has become a global outbreak. As of April 7, 2020, a total of 1,279,122 confirmed cases and 72,614 deaths have been recorded globally. [3] The cumulative number of confirmed cases in Spain, Italy, Germany and some other countries have exceeded 100,000, [3] and the number even exceeded 330,000 in the United States.

Although most COVID-19 patients had mild symptoms and got better after symptomatic support treatment, once they develop into a severe illness, many patients will quickly progress to acute respiratory distress syndrome (ARDS) or even multiple organ dysfunction syndrome (MODS) and increase the risk of death. [4] Since the fatality rate of severe or critically ill patients was over 50%, [5] the control of the number of patients with severe or critically ill COVID-19 has become one of the focal points and difficulties in epidemic prevention and control. Therefore, it is very important to master the clinical characteristics of severe or critically ill COVID-19 patients in order to help in judging the trend of severe disease as early as possible.

Various studies have been published on the clinical characteristics of patients with severe or critically ill COVID-19, [6] [7] [8] [9] however, most of them were single-center studies with a small sample size, and the reported results were not completely consistent. Therefore, we carried out this meta-analysis to collect the latest literatures to systematically analyze the clinical characteristics of patients with severe or critically ill COVID-19, so as to provide references for further research and clinical decisions.

This meta-analysis was conducted based on the guidelines of the Preferred Reporting Items for Meta-Analyses of Observational Studies in Epidemiology (MOOSE) Statement. [10] PubMed, Embase, WanFang, Chinese Biomedical Literature Database and China National Knowledge Infrastructure databases were electronically searched to collect studies describing clinical characteristics of severe or critically ill COVID-19 patients and published between January 1, 2020 and April 12, 2020. We also manually searched all the references of the included studies in order to identify eligible studies. If duplicate studies describing the same population, only the most detailed or recent study was included. There was no language restriction during the literature search, but we only included the literatures published online. The terms we used, both separately and in combination, included: "Coronavirus" OR "SARS-CoV-2" OR "2019-nCoV" OR "COVID-19" AND "severe" OR "critical" OR "critically ill" OR "icu care" OR "death".

The inclusion criteria included:

1. Case-control studies, cohort studies and case series studies; 2. The study population were the confirmed cases of severe or critically ill COVID-19 patients. Those received ICU care, mechanical ventilation or death also included. 3. The outcomes were clinical symptoms, laboratory findings and complications.

The exclusion criteria included:

Overlapping studies or duplicate studies describing the same population; 2. Studies with a sample size less than 20.

All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

Three reviewers independently collected the literature, and extracted the required data. Disagreements were resolved by discussion or consultation with another researcher. We screened the titles and abstracts firstly to identify the eligible studies. After that, we performed a full-text review to extract the detailed data. If necessary, we would contact the authors in order to collect further information. The data we extracted included: the surname of the first author and the publication time of the included studies, sample size, study design, study population, age and outcomes; relevant information of bias risk assessment. All of the included studies were observational studies, therefore, 3 reviewers independently evaluated study quality based on the guidelines of the British National Institute for Clinical Excellence (NICE). [11] We conducted the evaluation based on 8 criteria, and studies with a score greater than 4 were considered highquality studies (total score = 8).

The statistical analyses were performed by using STATA (version 12). Firstly, the original incidence rates r was converted by double arcsine to conform to the normal distribution, and then the metaanalysis of transformed rate tr was carried out. Finally, the pooled incidence rates R and its 95%CI are obtained by converting the results with the formula R = [sin (tr/2)] 2 . The heterogeneity among studies was analyzed by using a Chi-Squared test (P < . 10) and quantified by using the I 2 statistic. If there was no statistical heterogeneity among the results, the fixed effect model was used for meta-analysis. If statistical heterogeneity existed among the results, sensitivity analysis was used to explore the source of heterogeneity, and the random effect model was used for meta-analysis after the exclusion of obvious clinical heterogeneity. According to the funnel plot and the Egger and Begg tests to judge whether there was publication bias. A twotailed P < .05 was considered statistically significant.

A total of 2538 articles were identified after initial retrieval from databases, 277 additional records were identified from the Chinese Medical Journal Network. After removing the duplicates and screening carefully based on the inclusion criteria and exclusion criteria, 40 unique studies [6] [7] [8] [9] involving 2459 patients with severe COVID-19 were included in this metaanalysis ( Fig. 1 ).

A total of 40 retrospective studies [6] [7] [8] [9] were included, including 25 in English and 15 in Chinese, which were published between February 7, 2020 and April 7, 2020. 38 of the studies were set in China, and the other 2 studies were set in America. All the included studies received quality scores of 6-8, and considered high-quality studies (Tab.1).

3.3.1. Gender distribution. Relevant data regarding the clinical characteristics of 2459 COVID-19 patients were collected. Heterogeneity was significant across the included studies (I 2 = 64.9%), therefore, we used a random-effects model in this metaanalysis. We found that 62.3% (95%CI 58.8-65.8) of the patients were male (Fig. 2 

A sensitivity analysis was carried out by excluding each study one by one and reanalyzing the entire dataset. The pooled incidence rates did not change substantially, indicating that the results of this study were reliable and stable. Sensitivity analysis of the incidence rate of dyspnea in severe or critically ill COVID-19 patients were shown in Fig. 5 .

The p values derived using the Egger and the Begg test for all outcomes showed no obvious publication bias (Tab.4). A funnel plot based on the incidence rate of fever showed p values of 0.022 in Egger test and 0.733 in Begg test (Fig. 6 ). These results indicated that there was no publication bias. [48] Although the fatality rate of COVID-19 was lower than that of SARS and MERS, [49] [50] [51] it had a stronger transmissibility. [52] With the rapid increase in the number of confirmed COVID-19 worldwide, the death toll has already surpassed that of SARS and MERS. [48] Since the fatality rate of severe or critically ill COVID-19 patients was high, it is of great significance to master the clinical characteristics of severe or critically ill patients so as to help to identify and diagnose severe cases at an early stage and reduce the number of deaths.

In this study, we analyzed the clinical characteristics of 2,459 patients with severe or critically ill COVID-19. The results showed that the 2 main clinical symptoms were fever (87.4%) and cough (66.3%), which was basically consistent with the results of Cao et al. [53] Compared to previous results, [53, 54] our findings reveal the incidence rate of dyspnea (45.3%) was significant higher in severe or critically ill COVID-19 patients. This result highlights the importance of intense monitoring and evaluation of the disease of those presented with dyspnea. Most severe or critically ill COVID-19 patients showed lymphopenia (70.3%) and normal leukocyte counts (56.9%), confirming the viral origin of the disease. Xu et al [55] pointed out in the pathologic anatomic report of COVID-19 patients that novel coronavirus induces lymphocyte clearance and inhibits immune function, which is a potential immunological mechanism for the occurrence and progression of COVID-19. As Du et al said in their study, a majority (82.6%) of decedents demonstrated a remarkable lymphopenia. [43] So dynamic monitoring of changes of lymphocyte count and immune indicators may be an important indicator for dynamic assessment of disease status and prediction of disease outcome.

However, there was a large proportion of patients also along with elevated levels of inflammatory markers such as C-reactive protein levels (83.5%) and procalcitonin (36.6%). A recent metaanalysis by Lippi et al, [56] showed that increased values of procalcitonin were associated with a nearly 5-fold higher risk of severe infection. Since the production and release into the circulation of procalcitonin from extrathyroidal sources is enormously amplified during bacterial infections, [56] suggesting that severe cases were more likely presented with bacterial infections, so serial procalcitonin measurement may play a role for predicting evolution towards a more severe form of the disease. We also found a substantial proportion of severe or critically ill COVID-19 patients showed elevated levels of Ddimer (73.3%). Another meta-analysis [57] indicated that D-dimer values were higher in severe COVID-19 patients than in those without severe disease (WMD: 2.97 mg/L;95% CI: 2.47-3.46 mg/L). Therefore, D-dimer measurement may be associated with evolution toward worse clinical picture in COVID-19 patients. Grasselli et al retrospective analyzed 1591 consecutive patients requiring treatment in an intensive care unit (ICU) in Italy, showed that 99% of these patients needed respiratory support, including 88% who received mechanical ventilation and 11% who received noninvasive ventilation. [58] Also in our study, the incidence rate of ARDS in severe or critically ill cases was significantly increased compared to previous study. [60] In addition, other complications such as acute cardiac injury (37.1%), shock (32.0%), and acute kidney injury (22.0%) also common in severe or critically ill COVID-19 patients. So intense monitoring and evaluation of the functions of important organs in COVID-19 patients should be considered.

This meta-analysis included a large number of studies with large sample size, and all the included studies were of high quality. After the sensitivity analysis of each study was carried out, the results did not change substantially, indicating that the results of this study were reliable and stable. However, there were some limitations in our meta-analysis. Firstly, most of the included studies were single-center studies, so there may be admission deviation and selection deviation. Secondly, the sample size of included studies was small, the test efficiency may be insufficient. Thirdly, all the included studies in our metaanalysis were retrospective studies, it was hard to control the influence of confounding factors. Lastly, this meta-analysis indicated a significant heterogeneity among the studies which may affect the accuracy of the results of our meta-analysis.

In summary, the most common symptoms of severe or critically ill COVID-19 patients were fever and cough. Most patients showed lymphopenia, elevated levels of C-reactive protein and D-dimer. A large percentage of patients progress to ARDS, acute cardiac injury, acute kidney injury and shock were also common. Due to the limitation of quality and quantity of the included studies, the above conclusions need to be confirmed by more high-quality studies. 

Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)

WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it

WHO. Coronavirus disease 2019

National Health Commission Office. The guideline for treatment plan for severe andcritical cases of novel coronavirus pneumonia

Latest research advances on novel coronavirus pneumonia

Comparison of CT imaging and clinical featuresbetween common and severe/critical type of COVID-19 patients

Clinical characteristics of 463 patients with common and severe type coronavirus disease 2019

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical characteristics of fatal and recovered cases ofcoronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Meta-analysis of observational studies in epidemiology: a proposal for reporting

Appendix 4 Quality of case series form

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Clinical features of 62 cases of Coronavirus Disease 2019 complicated with acute renal injury

Clinical characteristics of 140 patients infected bySARS-CoV-2 in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Epidemiological and clinical characteristics analysisof severe and critical corona virus disease

Clinical features of deaths in the novel coronavirus epidemic in China

Clinical Characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan, China. XXXX Check for updates

Clinical features and treatment of COVID-19 patients in northeast Chongqing

The clinical features of the 143 patients with COVID-19 in North-East of Chongqing

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumoniain Wuhan

Clinical Characteristics of 223 Cases of COVID -19 in Chongqing

Clinical characteristics, treatment, and prognosis in 89 cases of COVID-2019

Retrospective study on the epidemiological characteristics of 139 patients with novel coronavirus pneumonia on the effects of Severity

The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia

Clinical features and treatment of 79 cases of pneumonia infected by COVID-19JT

Covid-19 in Critically Ill Patients inthe Seattle Region -Case Series

Clinical Characteristics of 91 Novel Coronavirus Pneumonia Patients In Jingmen First People's Hospital. Inner Mongolia Med Univers

Characteristicsand Outcomes of 21 Critically Ill PatientsWith COVID-19 in Washington State

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Retrospective Analysis of COVID-19 Patients with Different Clinical Subtypes

Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. XXX Check for updates

Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. XXXX Check for updates

Analysis of clinical features of 58 patients with severe or critical 2019 novel coronavirus pneumonia

Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients

A correlation study of CT and clinical features ofdifferent clinical types of 2019 novel coronavirus pneumonia

Analysis of clinical features of 153 patients with novel coronavirus pneumonia in Chongqing

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

COVID-19 in a Designated Infectious Diseases Hospital Outside Hubei Province, China. XXXX Check for updates

Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China

Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan

Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center

Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19

Clinical Features of 85 Fatal Cases of COVID-19 fromWuhan: A Retrospective Observational Study

Epidemiological patterns of coronavirus diseases

Special expert group for control of the epidemic of novel coronavirus pneumonia ofthe Chinese preventive medicine associationAn update on the epidemiological charac teristics of novel coronavirus pneumo-niaCOVID-19

Severe acute respiratory syndrome: historical, epidemiologic, and clinical features

The Middle East Respiratory Syndrome (MERS)

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis

novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis

Baseline Characteristics and Outcomes of 1591Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Medicine (2021) 100:5 www.md-journal